Haematopathology
COMPREHENSIVE HAEMATOPATHOLOGY OFFERING
Specialised Reporting of Haematological Malignancies
The diagnosis of complex haematological malignancies, and the provision of invaluable prognostic information, is further enhanced by our specialised NGS and diagnostic flow cytometric immunophenotyping services.
The accurate diagnosis and effective management of complex haematological malignancies, alongside the provision of invaluable prognostic information, are profoundly enhanced by our specialised services. Our comprehensive offering integrates cutting-edge Next-Generation Sequencing (NGS) and diagnostic flow cytometric immunophenotyping.
specialised reporting for HAEMATOLOGICAL MALIGNANCIES
Bone Marrow Reporting
Delivering a comprehensive evaluation of bone marrow through the integration of various diagnostic approaches, enabling accurate diagnosis, relevant prognostic information and assisting in the management of haematological malignancies.
- Sample processing and staining of bone marrow aspirate and trephine biopsy samples.
- Specialised use of cytochemistry and IHC markers to assist with the assessment of cell morphology, bone marrow structure and architecture.
- Comprehensive bone marrow evaluation and clinical reporting as per the International Council for Standardisation in Haematology (ICSH).
COMPREHENSIVE ANALYSIS OF HAEMATOLOGICAL MALIGANCIES
Collaborative Precision. Expert Solutions. Driving Cancer Advancements.
The diagnosis of complex haematological malignancies, and the provision of invaluable prognostic information, is further enhanced by our specialised NGS and diagnostic flow cytometric immunophenotypingservices.
Integrated Expertise. Consultative Approach.
Blood cancers, including leukaemia, lymphoma, and myeloma, are complex diseases. Despite medical advances improving diagnosis and treatment, their incidence continues to rise. It is estimated that more than 275,000 Australians will be living with a blood-based cancer or disorder by the year 2035.
- Our molecular haematology offering is underpinned by the expertise of the Wilson Centre for Blood Cancer Genomics at Peter MacCallum Cancer Centre, co-led by Associate Professor Piers Blombery and supported by Associate Professor David Westerman. This direct access to world-renowned clinicians and researchers ensures that our diagnostic services are at the forefront of precision haematology.
- Nexomics' haematology laboratory also provides a consultative molecular service, advising on appropriate NGS testing and participating in multidisciplinary meetings with haematologists, geneticists, and scientific staff to discuss complex patient cases, ensuring truly integrated care.
Precision Flow Cytometry
Our diagnostic flow cytometric immunophenotyping services go beyond basic characterisation, offering:
- Advanced insights into immune cell populations, detection of measurable residual disease (MRD), and monitoring of treatment responses.
- Measurable residual disease (MRD) testing in lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia and myeloma.
- Immunophenotypic characterisation of T-cell clonality by TRBC expression.
- Immunophenotypic quantification and characterisation of CART expressing T-cells post CART therapy.
